
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 25 years ago
Introductionalmost 25 years ago
The Managed Care Pharmacy Perspectivealmost 25 years ago
CPE Quiz





